Skip to main content

Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders

Guest Editors:
Charlotte TeunissenAmsterdam UMC, the Netherlands
Everard (Jort) VijverbergAmsterdam UMC, the Netherlands

Submission Status: Open   |   Submission Deadline: 30 September 2023

Alzheimer's Research & Therapy is calling for submissions to our Collection on Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders.

About the collection

The scientific field of neurodegenerative dementias has made significant progress over the last two decades. The diagnosis for these progressive neurodegenerative diseases is increasingly shifting from syndromal, based on signs and symptoms, to a biological construct based on the pathological hallmarks. For Alzheimer's disease (AD) it is amyloid β deposition, pathologic tau, neurodegeneration, and it is expected that analysis of alfa-synuclein (e.g. by aggregating assays) can contribute to an accurate diagnosis and to define progression and treatment effects. Furthermore, numerous genetic risk factors have been identified providing further insight into the pathways underpinning dementias.

Analogous to this significant progress in making an accurate diagnosis and a better understanding in dementia disorders, the drug development landscape for disease modifying therapies also grows. Especially in AD, amyloid-targeting therapies are now showing potential, while it is clear that multitarget interventions are probably needed to better silence these diseases. Moreover, drugs against targets that play a key role in several neurodegenerative diseases can be applied across diseases.

  1. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  2. Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...

    Authors: Young Min Choe, Guk-Hee Suh, Boung Chul Lee, Ihn-Geun Choi, Hyun Soo Kim, Jong Wan Kim, Jaeuk Hwang, Dahyun Yi and Jee Wook Kim
    Citation: Alzheimer's Research & Therapy 2023 15:143

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.